Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis
For asymptomatic mCRC with synchronous unresectable distant metastasis, PTR following first-line therapy with bevacizumab plus FOLFIRI may provide a potential survival benefit, particularly in stage IVA/IVB patients compared with stage IVC patients. Additionally, RT for primary tumor did not provide an additional OS benefit in mCRC with unresectable metastasis. A prospective randomized trial with a larger sample size is essential to further elucidate the role of PTR in this context.
Authors
- Peng-Jen Huang (ORCID: https://orcid.org/0000-0002-4495-0900)
- Tsung-Kun Chang
- Jaw‐Yuan Wang (ORCID: https://orcid.org/0000-0002-7705-2621)
- Po-Jung Chen
- Yen‐Cheng Chen (ORCID: https://orcid.org/0000-0001-6894-0937)
- Hsiang-Lin Tsai
- Ching‐Wen Huang (ORCID: https://orcid.org/0000-0002-3707-2003)
- Yung-Sung Yeh
- Po-Hsiang Yang
- Wei-Chih Su
Institutions
- Kaohsiung Medical University (TW)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- International Journal of Colorectal Disease
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1007/s00384-024-04745-1
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- Taiwan Biobank
- Academia Sinica
- Kaohsiung Medical University
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- National Science and Technology Council